To confirm whether all the TP53 wild-type cancer cells had similar synergistic effects or were the effect cell line specific, hence two additional TP53 wild-type cancer cell lines (RT4 and MCF7) were treated with XR-2 and NMDi alone or in combination (Fig. S3A, B). The gene discussed is TP53; the disease is cancer.